Sponsor

Corporal Michael J. Crescenz VA Medical Center

Clinical research sponsor

Published trials13
Recruiting shown2
Roles2
SourceClinicalTrials.gov

Clinical trials

13 shown
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as CorrelatesNCT03495024 · lead sponsor · 2019-01-01
RECRUITING
Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson DiseaseNCT07627529 · lead sponsor · 2026-06-01
NOT_YET_RECRUITING
Developing Personalized Medicine Strategies to Increase Physical Activity in Parkinson's Disease (PD) Through Digital Health TechnologyNCT05529121 · lead sponsor · 2021-12-03
COMPLETED
Degenerative Nigrostriatal Dysfunction in Drug-induced ParkinsonismNCT02361255 · lead sponsor · 2015-02-01
UNKNOWN
Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using MidodrineNCT02365012 · lead sponsor · 2014-04-01
UNKNOWN
Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial FunctionNCT01961453 · lead sponsor · 2013-08-01
WITHDRAWN
Study of Default Options in Advance DirectivesNCT01817686 · lead sponsor · 2013-03-01
COMPLETED
Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise CapacityNCT01919177 · lead sponsor · 2013-01-01
COMPLETED
Vasodilator Therapy for Heart Failure and Preserved Ejection FractionNCT01516346 · lead sponsor · 2012-01-01
COMPLETED
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.NCT05422911 · collaborator · 2022-08-31
RECRUITING
Unmet Social Needs StudyNCT04977583 · collaborator · 2022-04-29
COMPLETED
High-quality COPD Care for People With Immune Dysfunction Through Proactive E-consultsNCT03856879 · collaborator · 2019-05-21
COMPLETED
Treatment Preference and Patient Centered Prostate Cancer CareNCT02032550 · collaborator · 2013-06-01
COMPLETED

Sponsor roles

lead sponsor9
collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.